AEON Biopharma (NASDAQ:AEON - Free Report) had its price objective decreased by HC Wainwright from $18.00 to $6.00 in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.
AEON Biopharma Stock Performance
Shares of NASDAQ:AEON traded down $0.11 during trading on Wednesday, reaching $1.52. The stock had a trading volume of 105,756 shares, compared to its average volume of 69,632. AEON Biopharma has a 52 week low of $1.38 and a 52 week high of $17.17. The business's 50-day moving average price is $7.82 and its 200 day moving average price is $7.44.
AEON Biopharma (NASDAQ:AEON - Get Free Report) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.71) EPS for the quarter. As a group, sell-side analysts anticipate that AEON Biopharma will post -1.18 EPS for the current fiscal year.
Hedge Funds Weigh In On AEON Biopharma
Institutional investors have recently modified their holdings of the stock. Formidable Asset Management LLC acquired a new stake in shares of AEON Biopharma in the third quarter valued at approximately $360,000. Vanguard Group Inc. increased its stake in shares of AEON Biopharma by 261.8% in the 1st quarter. Vanguard Group Inc. now owns 758,992 shares of the company's stock valued at $8,804,000 after buying an additional 549,207 shares during the period. Finally, Atalaya Capital Management LP bought a new stake in shares of AEON Biopharma during the third quarter worth $19,827,000. 22.78% of the stock is owned by institutional investors.
AEON Biopharma Company Profile
(
Get Free Report)
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Featured Stories
Before you consider AEON Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AEON Biopharma wasn't on the list.
While AEON Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
